Jandali M
Clin Drug Investig. 2018; 38(6):503-508.
PMID: 29478238
DOI: 10.1007/s40261-018-0631-7.
Sheridan D, Attridge J
Pharmacoeconomics. 2013; 24 Suppl 2:35-54.
PMID: 23389487
DOI: 10.2165/00019053-200624002-00005.
Berger E, Patel K, Anwar S, Davies W, Sheridan D
Br J Clin Pharmacol. 2005; 60(1):17-23.
PMID: 15963089
PMC: 1884908.
DOI: 10.1111/j.1365-2125.2005.02371.x.
Donaldson K, Dawkins K, Waller D
Br J Clin Pharmacol. 1993; 36(4):315-21.
PMID: 12959309
PMC: 1364684.
DOI: 10.1111/j.1365-2125.1993.tb00370.x.
Little W, Cheng C, Elvelin L, NORDLANDER M
Cardiovasc Drugs Ther. 1995; 9(5):657-63.
PMID: 8573548
DOI: 10.1007/BF00878548.
Interactions of a new beta-blocker, celiprolol, with the calcium antagonists, diltiazem and nifedipine, on atrioventricular conduction.
Motomura S, Hashimoto K
Cardiovasc Drugs Ther. 1995; 9(3):445-57.
PMID: 8527355
DOI: 10.1007/BF00879034.
The treatment of heart failure--what next?.
Davies R, Sheridan D
Br J Clin Pharmacol. 1993; 35(6):557-63.
PMID: 8329279
PMC: 1381595.
DOI: 10.1111/j.1365-2125.1993.tb04181.x.
Hypertension in the elderly: age- and disease-related complications and therapeutic implications.
Lakatta E, Cohen J, Fleg J, Frohlich E, Gradman A
Cardiovasc Drugs Ther. 1993; 7(4):643-53.
PMID: 8241007
DOI: 10.1007/BF00877817.
How do calcium antagonists differ in clinical practice?.
Ferrari R, Cucchini F, Bolognesi R, Bachetti T, Boraso A, Bernocchi P
Cardiovasc Drugs Ther. 1994; 8 Suppl 3:565-75.
PMID: 7841090
DOI: 10.1007/BF00877225.
Primary pulmonary hypertension: effects of nifedipine.
Dalal J, Griffiths B, Henderson A
Br Heart J. 1981; 46(2):230-1.
PMID: 7272141
PMC: 482638.
DOI: 10.1136/hrt.46.2.230.
Nifedipine and beta-blockade as a cause of cardiac failure.
Robson R, Vishwanath M
Br Med J (Clin Res Ed). 1982; 284(6309):104.
PMID: 6797645
PMC: 1495693.
DOI: 10.1136/bmj.284.6309.104.
Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease.
Culling W, Ruttley M, Sheridan D
Br Heart J. 1984; 52(4):431-4.
PMID: 6477781
PMC: 481655.
DOI: 10.1136/hrt.52.4.431.
Nifedipine in the treatment of hypertension.
Brennan F, Flanagan M, Blake S, Cannon P
Eur J Clin Pharmacol. 1983; 25(6):713-5.
PMID: 6363097
DOI: 10.1007/BF00542507.
Acute and chronic haemodynamic and electrophysiological effects of nifedipine in patients receiving atenolol.
Rowland E, Razis P, Sugrue D, Krikler D
Br Heart J. 1983; 50(4):383-9.
PMID: 6354228
PMC: 481427.
DOI: 10.1136/hrt.50.4.383.
Vascular selectivity of felodipine.
LJUNG B
Drugs. 1985; 29 Suppl 2:46-58.
PMID: 3987552
DOI: 10.2165/00003495-198500292-00011.
Effects of felodipine on resistance and capacitance vessels in patients with essential hypertension.
Muir A, Wathen C, Hannan W
Drugs. 1985; 29 Suppl 2:59-65.
PMID: 3921338
DOI: 10.2165/00003495-198500292-00012.
Comparative trial of felodipine and nifedipine in refractory hypertension.
Aberg H, Lindsjo M, Morlin B
Drugs. 1985; 29 Suppl 2:117-23.
PMID: 3886357
DOI: 10.2165/00003495-198500292-00021.
Diltiazem treatment for the management of ischaemia in patients with poor left ventricular function: safety of long term administration.
Zema M, Perlmutter S, Mankes S, Nikitopoulos C
Br Heart J. 1987; 58(5):512-7.
PMID: 3676040
PMC: 1277349.
DOI: 10.1136/hrt.58.5.512.
Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.
Echizen H, Eichelbaum M
Clin Pharmacokinet. 1986; 11(6):425-49.
PMID: 3542336
DOI: 10.2165/00003088-198611060-00002.
Changes in haemodynamics and left ventricular function during intravenous nifedipine infusion with and without additional propranolol in patients with coronary artery disease. A randomized, placebo controlled trial.
Mauser M, Voelker W, Roser D, Karsch K, Seipel L
Eur J Clin Pharmacol. 1987; 33(4):345-8.
PMID: 3327697
DOI: 10.1007/BF00637628.